Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of ZY002 gynecologic gel for persistent high-risk cervical HPV infection
CTR20252363Phase 2Active
- Sponsor
- Jiangsu Zhengyang Pharmaceutical
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ZY002 in human papillomavirus infection, cervical human papillomavirus infection, sponsored by Jiangsu Zhengyang Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
ZY002
03
Conditions
human papillomavirus infectioncervical human papillomavirus infection
Beyond the preview
Go deeper on CTR20252363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252363.